Actavis Namenda case could trigger more 'product hopping' scrutiny
This article was originally published in Scrip
Actavis tried to persuade a three-judge panel from the US Court of Appeals for the Second Circuit in New York on 13 April to lift an injunction imposed by a lower court preventing the company from pulling its twice-daily immediate-release version of its Alzheimer's dementia drug Namenda (memantine hydrochloride) from the US market in light of a more updated form of the medicine.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.